Invention Grant
- Patent Title: (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity
-
Application No.: US16680605Application Date: 2019-11-12
-
Publication No.: US11267804B2Publication Date: 2022-03-08
- Inventor: Patrick Rene Angibaud , Olivier Alexis Georges Querolle , Didier Jean-Claude Berthelot , Christophe Meyer , Matthieu Philippe Victor Willot , Lieven Meerpoel , Thierry Francois Alain Jean Jousseaume
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Priority: EP15189163 20151009,EP16174710 20160616
- Main IPC: C07D241/44
- IPC: C07D241/44 ; C07D403/10 ; C07D403/12 ; C07D403/14 ; C07D498/10 ; C07D487/02 ; C07D241/14 ; C07D403/06 ; C07D417/04 ; C07D403/04 ; C07D413/04 ; C07D401/06 ; C07D513/10 ; C07D491/10 ; C07D413/06 ; C07D401/04 ; C07D413/14 ; C07D495/04 ; C07D241/42 ; C07D413/10 ; C07D471/04 ; C07D487/04 ; C07D495/10
Abstract:
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
Public/Granted literature
- US20200079763A1 QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS A PI3KB INHIBITORS Public/Granted day:2020-03-12
Information query
